• Profile
Close

Insulin regimens and glycemic control in different parts of Europe over 4 years after starting insulin in people with type 2 diabetes: Data from the CREDIT non-interventional study

Diabetes Research and Clinical Practice Sep 04, 2017

Blonde L, et al. – Researchers intended to present how insulin therapy evolves in type 2 diabetes (T2DM) in clinical practice in regions of Europe. The data indicated HbA1c and prevalence of complications were higher in eastern Europe (EEur) when starting insulin. Regional differences exist in choice of insulin regimens in Europe. Nevertheless, people starting insulin enhanced and sustained their glycemic control regardless of regional differences or insulin regimens applied.

Methods
  • Researchers collected data from people starting any insulin in eastern Europe (EEur: Croatia, Russia, Ukraine), northern Europe (NEur: Finland, Germany, UK) and southern Europe (SEur: France, Italy, Portugal, Spain).
  • They extracted retrospective data on starting insulin and prospective follow–up data from clinical records.

Results
  • 1699 (76.0%) of 2236 eligible people had data at 4 years.
  • It was demonstrated that EEur participants were mostly female, younger and had shorter diabetes duration on starting insulin, yet had highest baseline HbA1c and more micro–/macro–vascular disease.
  • A majority (60%–64%) in all regions started on basal insulin alone, declining to 30%–38% at 4 years, with most switching to basal+mealtime insulin regimen (24%–40%).
  • They found higher baseline (28%) and 4–year use (34%) of premix insulin in NEur.
  • Alteration in HbA1c (SD) ranged from –1.2 (2.1)% (–13 [23] mmol/mol) in NEur to –2.4 (2.0)% (–26 [22] mmol/mol) in EEur.
  • Remarkably, weight change ranged from +1.9 (8.3) kg in NEur to +3.2 (7.0) kg in SEur.
  • As per the data, overall documented hypoglycemia ranged from 0.3 (1.3) to 1.3 (4.4) events/person/6–months (NEur vs. EEur, respectively) and was stable with time.
  • It was indicated that severe hypoglycemia rates remained low.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay